Michael Crump

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 141 publications

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: June 15, 2026

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Journal: Blood neoplasia

Published: January 09, 2026

End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study.

End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study.

Journal: British journal of haematology

Published: December 29, 2025

Real-world outcomes in adult histiocytosis: the uncharted territory of orphan diseases.

Real-world outcomes in adult histiocytosis: the uncharted territory of orphan diseases.

Journal: Leukemia & lymphoma

Published: November 13, 2025

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Journal: Hematological oncology

Published: November 03, 2025

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

Journal: British journal of haematology

Published: October 17, 2025

Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.

Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.

Journal: Blood advances

Published: September 24, 2025

Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.

Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.

Journal: Blood advances

Published: September 24, 2025

Detection and classification of lymphoma from cell-free methylome data.

Detection and classification of lymphoma from cell-free methylome data.

Journal: NPJ precision oncology

Published: August 26, 2025

Management and Outcomes for Patients With Hodgkin Lymphoma With Partial Metabolic Response After First-Line Systemic Therapy.

Management and Outcomes for Patients With Hodgkin Lymphoma With Partial Metabolic Response After First-Line Systemic Therapy.

Journal: Practical radiation oncology

Published: August 06, 2025

Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma.

Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma.

Journal: JCO precision oncology

Published: July 09, 2025

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.

Journal: Hepatology communications

Published: June 16, 2025

Showing 1-12 of 141

Last Updated: 09/26/2026